Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 13/20 | 0.41 |
| ▸ | CA2 | P00918 | 13/20 | 0.41 |
| ▸ | CA12 | O43570 | 11/20 | 0.41 |
| ▸ | CA9 | Q16790 | 11/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 6/20 | 0.39 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1824894 | 0.83 | CA1 (0.42) | CA1CA2CA12CA9BTK | |
| SCHEMBL1818687 | 0.83 | BDKRB1 (0.48) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL1827385 | 0.81 | SLC40A1 (0.46) | CA1CA2BTK | |
| SCHEMBL1823479 | 0.73 | CA1 (0.55) | CA1CA2CA12CA9CA4 | |
| SCHEMBL1825015 | 0.73 | PDE4A (0.43) | CA1CA2CA12CA9CA4 | |
| SCHEMBL1823409 | 0.73 | CA1 (0.43) | CA1CA2CA12CA9BTK | |
| SCHEMBL12655356 | 0.72 | SLC40A1 (0.46) | CA1CA2BTK | |
| SCHEMBL1820671 | 0.72 | LMNA (0.42) | CA1CA2CA12CA9BTK | |
| SCHEMBL1825541 | 0.72 | ALDH1A1 (0.45) | CA1CA2CA12CA9KDM4E | |
| SCHEMBL2409582 | 0.72 | CA1 (0.42) | CA1CA2CA12CA9BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212918-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| WO-2011060199-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212918-A1 | BORON-CONTAINING SMALL MOLECULES | BCL6B, BCL6, BTD | CA1 4452/4885CA2 1155/4885CA12 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.